1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. Escalon Medical Corp.
  6. News
  7. Summary
    ESMC   US2960743050

ESCALON MEDICAL CORP.

(ESMC)
Delayed OTC Markets  -  01:44 2022-08-02 pm EDT
0.1042 USD   +12.83%
05/13ESCALON MEDICAL CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
05/13Escalon Medical Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022
CI
02/14ESCALON MEDICAL CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ESCALON MEDICAL CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)

05/13/2022 | 04:35pm EDT

Forward Looking Statements


  Certain statements contained in, or incorporated by reference in, this report
are forward-looking statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995, which provide current
expectations or forecasts of future events. Such statements can be identified by
the use of terminology such as "anticipate," "believe," "could," "estimate,"
"expect," "forecast," "intend," "may," "plan," "possible," "project," "should,"
"will," and similar words or expressions. The Company's forward-looking
statements include certain information relating to general business strategy,
growth strategies, financial results, liquidity, the Company's ability to
continue as a going concern, discontinued operations, research and development,
product development, the introduction of new products, the potential markets and
uses for the Company's products, the Company's ability to increase its sales
campaign effectively, the Company's regulatory filings with the FDA,
acquisitions, dispositions, the development of joint venture opportunities,
intellectual property and patent protection and infringement, the loss of
revenue due to the expiration or termination of certain agreements, the effect
of competition on the structure of the markets in which the Company competes,
increased legal, accounting and Sarbanes-Oxley compliance costs, information
security, cybersecurity and data privacy risks, defending the Company in
litigation matters and the Company's cost saving initiatives. The reader must
carefully consider forward-looking statements and understand that such
statements involve a variety of risks and uncertainties, known and unknown, and
may be affected by assumptions that fail to materialize as anticipated,
including risks related to the COVID-19 pandemic, inflation, and other risks
described in the Company's Form 10-K for the fiscal year ended June 30, 2021.
Consequently, no forward-looking statement can be guaranteed, and actual results
may vary materially. It is not possible to foresee or identify all factors
affecting the Company's forward-looking statements, and the reader therefore
should not consider the list of such factors contained in its periodic report on
Form 10-K for the year ended June 30, 2021 and this Form 10-Q quarterly report
to be an exhaustive statement of all risks, uncertainties or potentially
inaccurate assumptions.

Executive Overview-nine-month periods ended March 31, 2022 and 2021


The following highlights are discussed in further detail within this Form 10-Q.
The reader is encouraged to read this Form 10-Q in its entirety to gain a more
complete understanding of factors impacting Company performance and financial
condition.


•Consolidated net revenue increased approximately $155,000 or 2.0%, to
$7,792,000 during the nine months ended March 31, 2022, as compared to the same
period of last fiscal year. The increase in net revenue is attributed to an
increase in sales in Sonomed's ultrasound products of $559,000 offset by a
decrease in Trek revenue of $144,000, a decrease in service plans revenue of
$168,000, and a decrease in sales of AXIS products of $92,000.


•Consolidated cost of goods sold totaled approximately $4,681,000, or 60.1%, of
total revenue for the nine months ended March 31, 2022, as compared to
$4,553,000, or 59.6%, of total revenue of the same period of last fiscal year.
The Increase of 0.5% in cost of goods sold as a percentage of total revenue is
mainly due to changes in product sales mix and geographic differences.


•Consolidated marketing, general and administrative expenses increased $221,000,
or 8.4%, to $2,855,000 for the nine months ended March 31, 2022, as compared to
the same period of last fiscal year. The increase in marketing, general

                                       17
--------------------------------------------------------------------------------

and administrate expenses is mainly due to increased sales compensation, increased expense for network improvement, consultant placement expense, increased trade show and travel expense.



•Consolidated research and development expenses increased $111,000, or 16.6%, to
$781,000 for the nine months ended March 31, 2022, as compared to the same
period of last fiscal year. Research and development expenses were primarily
expenses associated with the introduction of new or enhanced products. The
increase in research and development expense is mainly due to increased
consulting expense during the nine months ended March 31, 2022.

Company Overview

The following discussion should be read in conjunction with the interim unaudited condensed consolidated financial statements and the notes thereto, which are set forth in Item 1 of this report.


  The Company operates in the healthcare market specializing in the development,
manufacture, marketing and distribution of medical devices and pharmaceuticals
in the area of ophthalmology. The Company and its products are subject to
regulation and inspection by the FDA. The FDA requires extensive testing of new
products prior to sale and has jurisdiction over the safety, efficacy and
manufacture of products, as well as product labeling and marketing. The
Company's Internet address is www.escalonmed.com. Under the trade name of
Sonomed-Escalon the Company develops, manufactures and markets ultrasound
systems used for diagnosis or biometric applications in ophthalmology, develops,
manufactures and distributes ophthalmic surgical products under the Trek Medical
Products name, and manufactures and markets image management systems.

Critical Accounting Policies and Estimates

The preparation of unaudited condensed consolidated financial statements requires management to make estimates and assumptions that impact amounts reported therein. On a regular basis, we evaluate these estimates. These estimates are based on management's historical industry experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from these estimates.


For a description of the accounting policies that, in management's opinion,
involve the most significant application of judgment or involve complex
estimation and which could, if different judgment or estimates were made,
materially affect our reported financial position, results of operations, or
cash flows, see the notes to consolidated financial statements included in the
Form 10-K for the year ended June 30, 2021, as well as Note 3 to our unaudited
condensed consolidated financial statements for the three and nine months ended
March 31, 2022.

During the three and nine months ended March 31, 2022, there were no significant changes in our accounting policies and estimates to our unaudited condensed consolidated financial statements.

                                       18
--------------------------------------------------------------------------------

Results of Operations

Three and Nine Months Ended March 31, 2022 and 2021

The following table shows consolidated net revenue, as well as identifying trends in revenues for the three and nine months ended March 31, 2022 and 2021. Table amounts are in thousands:

                                        For the Three Months Ended March 31,                           For the Nine Months Ended March 31,
                                   2022               2021               % Change                2022               2021               % Change
Net Revenue:
Products                       $    2,260          $  2,098                     7.7  %       $    7,261          $  6,938                     4.7  %
Service plans                         156               227                   (31.3) %              531               699                   (24.0) %
Total                          $    2,416          $  2,325                     3.9  %       $    7,792          $  7,637                     2.0  %



Consolidated net revenue increased approximately $91,000 or 3.9%, to $2,416,000
during the three months ended March 31, 2022 as compared to the same period of
last fiscal year. The increase in net revenue is attributed to an increase in
sales in Trek revenue of $207,000, and an increase in Sonomed's ultrasound
products of $23,000 offset by a decrease in sales of AXIS products of $68,000,
and a decrease in service plans revenue of $71,000.

Consolidated net revenue increased approximately $155,000 or 2.0%, to $7,792,000
during the nine months ended March 31, 2022 as compared to the same period of
last fiscal year. The increase in net revenue is attributed to an increase in
sales in Sonomed's ultrasound products of $559,000 offset by a decrease in Trek
revenue of $144,000, a decrease in service plans revenue of $168,000, and a
decrease in sales of AXIS products of $92,000.

The following table presents the domestic and foreign sales for the three and
nine months ended March 31, 2022 and 2021. The table amounts are in thousands:
                                 For the Three Months Ended March 31,                                     For the Nine Months Ended March 31,
                                2022                                2021                                2022                                2021
Domestic           $   1,266              52.4  %       $ 1,107              47.6  %       $   4,251              54.6  %       $ 4,514              59.1  %
Foreign                1,150              47.6  %         1,218              52.4  %           3,541              45.4  %         3,123              40.9  %
Total              $   2,416             100.0  %       $ 2,325             100.0  %       $   7,792             100.0  %       $ 7,637             100.0  %



The following table presents consolidated cost of goods sold and as a percentage
of revenues for the three and nine months ended March 31, 2022 and 2021. Table
amounts are in thousands:

                                  For the Three Months Ended March 31,                                      For the Nine Months Ended March 31,
                        2022                %               2021               %                2022                 %               2021                %

Cost of Goods Sold:

                    $   1,478              61.2  %       $ 1,383              59.5  %            4,681              60.1  %          4,553              59.6  %
Total               $   1,478              61.2  %       $ 1,383              59.5  %            4,681              60.1  %          4,553              59.6  %



Consolidated cost of goods sold totaled approximately $1,478,000, or 61.2%, of
total revenue for the three months ended March 31, 2022, as compared to
$1,383,000, or 59.5%, of total revenue of the same period of last fiscal year.
The increase of 1.7% in cost of goods sold as a percentage of total revenue is
mainly due to changes in product sales mix and geographic differences.

Consolidated cost of goods sold totaled approximately $4,681,000, or 60.1%, of
total revenue for the nine months ended March 31, 2022, as compared to
$4,553,000, or 59.6%, of total revenue of the same period of last fiscal year.
The increase of 0.5% in cost of goods sold as a percentage of total revenue is
mainly due to changes in product sales mix and geographic differences.

The following table presents consolidated marketing, general and administrative expenses for three and nine months ended March 31, 2022 and 2021. Table amounts are in thousands:

                                       19
--------------------------------------------------------------------------------


                                       20
--------------------------------------------------------------------------------

                                    For the Three Months Ended March 31,                              For the Nine Months Ended March 31,
                              2022               2021               % Change                   2022                 2021                % Change

Marketing, General and Administrative:

                          $    1,001          $    858                     16.7  %               2,855              2,634                       8.4  %
Total                     $    1,001          $    858                     16.7  %               2,855              2,634                       8.4  %



Consolidated marketing, general and administrative expenses increased $143,000,
or 16.7%, to $1,001,000 for the three months ended March 31, 2022, as compared
to the same period of last fiscal year. The increase in marketing, general and
administrate expenses is mainly due to increased sales compensation, increased
expense for network improvement, consultant placement expense, and increased
trade show and travel expense.

Consolidated marketing, general and administrative expenses increased $221,000,
or 8.4%, to $2,855,000 for the nine months ended March 31, 2022, as compared to
the same period of last fiscal year. The increase in marketing, general and
administrate expenses is mainly due to increased sales compensation, increased
expense for network improvement, consultant placement expense, and increased
trade show and travel expense.

The following table presents consolidated research and development expenses for the three and nine months ended March 31, 2022 and 2021.

Table amounts are in thousands:

                                                  For Nine Months Ended March 31,                                 For Nine Months Ended March 31,
                                       2022                 2021               % Change                    2022                 2021               % Change
Research and Development:
                                $           229          $    216                      6.0  %                   781          $    670                    16.6  %
Total                           $           229          $    216                      6.0  %       $           781          $    670                    16.6  %


=

Consolidated research and development expenses increased $13,000, or 6.0%, to
$229,000 for the three months ended March 31, 2022, as compared to the same
period of last fiscal year. Research and development expenses were primarily
expenses associated with the introduction of new or enhanced products. The
increase in research and development expense is mainly due to increased
consulting expense during the three months ended March 31, 2022.

Consolidated research and development expenses increased $111,000, or 16.6%, to
$781,000 for the nine months ended March 31, 2022, as compared to the same
period of last fiscal year. Research and development expenses were primarily
expenses associated with the introduction of new or enhanced products. The
increase in research and development expense is mainly due to increased
consulting expense during the nine months ended March 31, 2022.


Other income (expense)


On April 27, 2020, the Company entered into a PPP loan for $500,000 in
connection with the CARES Act related to COVID-19. The promissory note has a
fixed payment schedule. The PPP loan is unsecured. A final payment for the
unpaid principal and accrued interest will be payable no later than two years
after the funding date. The note will bear interest at a rate of 1.00% per
annum. The Company submitted the loan forgiveness application on August 2, 2021.
The full amount of the PPP loan and accrued interest of $6,305 were forgiven on
August 13, 2021 and reported as other income during the nine-month period ended
March 31, 2022.


COVID-19 Disclosure

  On March 11, 2020, the World Health Organization declared the outbreak of a
coronavirus (COVID-19) a pandemic. This pandemic has had a significant impact on
the global and domestic economy and is likely to impact the operations of the
company. The Company has been assessing the impact of the COVID-19 pandemic on
the business, including the impact on the financial condition and results of
operations, financial resources, changes in accounting judgment as well as the
impact on the supply and demand, etc. The Company is considered an essential
business and was able to maintain operations during the lockdown. However, the
Company does not know the extent and duration of the impact of COVID-19 on its
business due to the uncertainty about the spread of the virus.
                                       21
--------------------------------------------------------------------------------

Russia-Ukraine War


In February 2022, Russia invaded Ukraine. As military activity proceeds and
sanctions, export controls and other measures are imposed by many countries
against Russia, Belarus and specific areas of Ukraine, the war is increasingly
affecting the global economy and financial markets, as well as exacerbating
ongoing economic challenges, including rising inflation and global supply-chain
disruption. The Company has operations or activities in countries and regions
outside the United States. As a result, its global operations are affected by
economic, political and other conditions in the foreign countries in which it
does business as well as U.S. laws regulating international trade, although the
Company has not yet assessed that the war has had a material effect on its
financial position or results of operations. The Company will continue to
monitor the impacts of the Russia-Ukraine war on macroeconomic conditions and
continually assess the effect these matters may have on customer demand,
suppliers' ability to deliver products, cybersecurity risks and the Company's
liquidity and access to capital.

Liquidity and Capital Resources


Our total cash on hand as of March 31, 2022 was approximately $1,049,000
excluding restricted cash of approximately $256,000 compared to approximately
$1,651,000 of cash on hand and restricted cash of $256,000 as of June 30, 2021.
Approximately $48,000 was available under our line of credit as of March 31,
2022.

Because the Company's operations have not historically generated sufficient revenues to enable profitability, we will continue to monitor costs and expenses closely and may need to raise additional capital in order to fund operations.


The Company expect to continue to fund operations from cash on hand and through
capital raising sources if possible and available, which may be dilutive to
existing stockholders, through revenues from the licensing of the Company's
products, or through strategic alliances. Additionally, we may seek to sell
additional equity or debt securities through one or more discrete transactions,
or enter into a strategic alliance arrangement, but can provide no assurances
that any such financing or strategic alliance arrangement will be available on
acceptable terms, or at all. Moreover, the incurrence of indebtedness in
connection with a debt financing would result in increased fixed obligations and
could contain covenants that would restrict our operations.

As of March 31, 2022 we had an accumulated deficit of approximately $68.9
million, incurred recurring losses from operations and negative cash flows from
operating activities. These factors raise substantial doubt regarding our
ability to continue as a going concern, and our ability to generate cash to meet
our cash requirements for the following twelve months as of the date of this
form 10-Q.


The following table presents overall liquidity and capital resources as of March 31, 2022 and June 30, 2021. Table amounts are in thousands:


                                                                          March 31,                 June 30,
                                                                            2022                      2021
Current Ratio:
Current assets                                                             $4,171                    $4,593
Less: Current liabilities                                                   2,976                     3,397
Working capital                                                            $1,195                    $1,196
Current ratio                                                             1.40 to 1                 1.35 to 1
Debt to Total Capital Ratio:
Line of credit, note payable, lease liabilities, and EIDL loan             $1,056                    $1,772
Total debt                                                                  1,056                     1,772
Total equity                                                                1,428                     1,460
Total capital                                                              $2,484                    $3,232
Total debt to total capital                                                 42.5%                     54.8%


                                       22
--------------------------------------------------------------------------------

Working Capital Position


Working capital decreased approximately $1,000 as of March 31, 2022, and the
current ratio increased to 1.40 to 1 from 1.35 to 1 when compared to June 30,
2021. The decrease in working capital is due to a decrease in current
liabilities of $421,000 during the quarter ended March 31, 2022, offset by a
decrease in current assets of $422,000. The PPP loan forgiveness mainly
contributes to the decrease of the current liabilities.

Debt to total capital ratio was 42.5% and 54.8% as of March 31, 2022 and June 30, 2021, respectively. The decrease of debt to total capital ratio is also due to the PPP loan forgiveness.

Cash Flow Used in (Provided By) Operating Activities


During the nine months ended March 31, 2022 the Company used approximately
$597,000 of cash in operating activities as compared to cash of approximately
$840,000 provided by operating activities during the nine months ended March 31,
2021.

  For the nine months ended March 31, 2022, its cash used in operations is
mainly as a result of net loss, including the non-cash adjustment for PPP loan
forgiveness, along with the increase in inventories of $128,000, an increase in
accounts receivable of approximately $63,000, a decrease in deferred revenue of
$61,000, a repayment of employer tax deferral of $41,000, and decrease in
operating liabilities of $217,000 offset by an increase in accrued expense of
$184,000. The remaining offsetting items for cash provided by operations is
comprised of less significant items.

  For the nine months ended March 31, 2021, its cash provided by operations is
mainly due to decreases in accounts receivable and inventory of approximately
$751,000, increase in accounts payable and accrued expenses of approximately
$234,000 offset by a decrease in deferred revenue of $22,000. The remaining
offsetting items for cash provided by operations is comprised of less
significant items. The change in the mentioned working capital accounts are due
to timing as well as the Company's focus on preserving cash due to uncertainty
in the current economic climate.

Cash Flows used in Investing Activities

Cash flows used in investing activities for the nine-month period ended March 31, 2021 was due to the purchase of equipment of $9,000.

Cash Flows Used in Financing Activities


For the nine months ended March 31, 2022 the cash used in financing activities
was due to an auto loan payment of employer $3,000 and repayment of EIDL loan of
$2,000. For the nine months ended March 31, 2021 the cash used in financing
activities of $3,000 was due to auto loan payment.

Debt Financing


  On June 29, 2018 the Company entered a business loan agreement with TD bank
receiving a line of credit evidenced by a promissory note of $250,000. The
interest is subject to change based on changes in an independent index which the
Wall Street Journal Prime. The index rate at the date of the agreement is 5.000%
per annum. Interest on the unpaid principal balance of the note will be
calculated using a rate of 0.740 percentage points over the index, adjusted if
necessary for any minimum and maximum rate limitations, resulting in an initial
rate of 5.740% per annum based on a year of 360 days. The interest rate was
5.00% as of March 31, 2022. The Company was required to put $250,000 in the TD
bank savings account as collateral.

  As of March 31, 2022 and June 30, 2021, the line of credit balance was
$201,575 with TD bank. The line of credit interest expense was approximately
$3,000 and $3,000 for the three months ended March 31, 2022 and 2021,
respectively. The line of credit interest expense was approximately $8,000 for
the nine months ended March 31, 2022 and 2021, respectively.

COVID-19 Relief Loans and Liabilities

Payroll Protection Program ("PPP")


  On April 27, 2020, the Company entered into a PPP loan for $500,000 in
connection with the CARES Act related to COVID-19. The promissory note had a
fixed payment schedule. The PPP loan was unsecured. A final payment for the
unpaid principal and accrued interest was payable no later than two years after
the funding date. The note bore interest at a rate of 1.00% per annum. The full
amount of the PPP loan and accrued interest were forgiven on August 13, 2021 and
reported as other income during the nine-month period ended March 31, 2022.

Economic Injury Disaster Loan ("EIDL")

                                       23
--------------------------------------------------------------------------------

  EIDL is designed to provide economic relief to businesses that are currently
experiencing a temporary loss of revenue due to the Coronavirus (COVID-19)
pandemic. EIDL proceeds can be used to cover a wide array of working capital and
normal operating expenses, such as continuation to health care benefits, rent,
utilities, and fixed debt payments. The Company received $150,000 EIDL loan. The
annual interest rate is 3.75%, the payment term is 30 years and the monthly
payment of $731 started on July 1st, 2021. The EIDL loan is secured by the
tangible and intangible personal property of the Company. The Company submitted
an EIDL loan increase application on May 6, 2022, increasing the loan amount
from $150,000 to $200,000. The loan modification is being proceed.

Employer Payroll Tax Withholding


  The CARES Act allows employers to defer the deposit and payment of
the employer share of Social Security tax that would otherwise be due on or
after March 27, 2020, and before January 1, 2021. The Company has deferred
approximately $82,000 of the social security tax. 50% of the deferred employment
taxes was paid before December 31, 2021. The remaining 50% is not due
until December 31, 2022. Approximately $41,000 was reported as short-term other
liabilities as of March 31, 2022.

© Edgar Online, source Glimpses

All news about ESCALON MEDICAL CORP.
05/13ESCALON MEDICAL CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
AQ
05/13Escalon Medical Corp. Reports Earnings Results for the Third Quarter and Nine Months En..
CI
02/14ESCALON MEDICAL CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
AQ
02/14Escalon Medical Corp. Reports Earnings Results for the Second Quarter and Six Months En..
CI
2021ESCALON MEDICAL CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
AQ
2021Escalon Medical Corp. Reports Earnings Results for the First Quarter Ended September 30..
CI
2021ESCALON MEDICAL : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
2021Escalon Medical Corp. Reports Earnings Results for the Full Year Ended June 30, 2021
CI
2021ESCALON MEDICAL : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
2021Escalon Medical Corp. Reports Earnings Results for the Third Quarter Ended March 31, 20..
CI
More news